Related references
Note: Only part of the references are listed.Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
David J. Graham et al.
CIRCULATION (2015)
Factor XII inhibition reduces thrombus formation in a primate thrombosis model
Anton Matafonov et al.
BLOOD (2014)
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits
Jonathan W. Yau et al.
BLOOD (2014)
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman et al.
CIRCULATION (2014)
Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
Elaine M. Hylek et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Thrombosis: a major contributor to the global disease burden
G. E. Raskob et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta- analysis
T. van der Hulle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Embolic strokes of undetermined source: the case for a new clinical construct
Robert G. Hart et al.
LANCET NEUROLOGY (2014)
Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
Jack E. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome
Jeffrey I. Weitz
THROMBOSIS AND HAEMOSTASIS (2014)
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Jonathan Douxfils et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
A specific antidote for dabigatran: functional and structural characterization
Felix Schiele et al.
BLOOD (2013)
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Ammar Majeed et al.
CIRCULATION (2013)
Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer
R. S. Woodruff et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Genmin Lu et al.
NATURE MEDICINE (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Amanda R. Harrington et al.
STROKE (2013)
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis
Luke Bamber et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism
Patrick Lefebvre et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control
Allan C. Skanes et al.
CANADIAN JOURNAL OF CARDIOLOGY (2012)
Prevention of VTE in Orthopedic Surgery Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Yngve Falck-Ytter et al.
CHEST (2012)
Antithrombotic Therapy for Atrial Fibrillation Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
John J. You et al.
CHEST (2012)
Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines
Clive Kearon et al.
CHEST (2012)
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial
Jeff S. Healey et al.
CIRCULATION (2012)
National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
Kate Kirley et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2012)
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
A. John Camm et al.
EUROPEAN HEART JOURNAL (2012)
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement POOLED ANALYSIS OF MAJOR VENOUS THROMBOEMBOLISM AND BLEEDING IN 8464 PATIENTS FROM THE ADVANCE-2 AND ADVANCE-3 TRIALS
G. E. Raskob et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran The RE-LY Trial
Robert G. Hart et al.
STROKE (2012)
Dabigatran and rivaroxaban for prevention of venous thromboembolism - systematic review and adjusted indirect comparison
Y. K. Loke et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2011)
Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payerʼs Perspective
Aurea Duran et al.
PHARMACOECONOMICS (2011)
Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
Isla M. Ogilvie et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Changes in surgical loads and economic burden of hip and knee replacements in the US: 1997-2004
Sunny Kim
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty
Richard J. Friedman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Robert G. Hart et al.
ANNALS OF INTERNAL MEDICINE (2007)
Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030
Steven Kurtz et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2007)
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events - Findings from the global orthopaedic registry
D. Warwick et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2007)
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence
Yoko Miyasaka et al.
CIRCULATION (2006)
Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
AS Go et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
